Pura Vida Investments LLC Sells 687,743 Shares of Metagenomi, Inc. $MGX

Key Points

• Pura Vida Investments sold 687,743 shares of Metagenomi in Q3, reducing its stake by 72.2% to 264,391 shares (about 0.70% of MGX, ~$627,000) and making MGX its sixth-largest holding (~4.0% of the firm's portfolio).
• Other institutions shifted positions too — notably JPMorgan Chase increased its stake by 4,155.7% to 62,559 shares and Bank of America grew its holding by 482.9% to 21,113 shares, while AQR, RBF Capital and Marshall Wace initiated new positions.
• MGX opened at $1.60 (52‑week range $1.23–$3.95) with a market cap of about $60.1M; analysts’ consensus is a "Moderate Buy" with a $10 target, though Weiss Ratings recently reiterated a "sell (d-)".

Pura Vida Investments LLC lessened its stake in Metagenomi, Inc. (NASDAQ:MGX - Free Report) by 72.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 264,391 shares of the company's stock after selling 687,743 shares during the quarter. Metagenomi comprises approximately 4.0% of Pura Vida Investments LLC's investment portfolio, making the stock its 6th biggest holding. Pura Vida Investments LLC owned approximately 0.70% of Metagenomi worth $627,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of MGX. Bank of America Corp DE grew its stake in shares of Metagenomi by 482.9% during the fourth quarter. Bank of America Corp DE now owns 21,113 shares of the company's stock valued at $76,000 after purchasing an additional 17,491 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Metagenomi by 4,155.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 62,559 shares of the company's stock worth $148,000 after buying an additional 61,089 shares in the last quarter. RBF Capital LLC acquired a new position in Metagenomi during the 2nd quarter worth $118,000. AQR Capital Management LLC bought a new position in Metagenomi in the 1st quarter valued at $119,000. Finally, Marshall Wace LLP acquired a new stake in shares of Metagenomi in the 2nd quarter valued at $222,000.

Metagenomi Price Performance

Shares of NASDAQ MGX opened at $1.60 on Thursday. Metagenomi, Inc. has a fifty-two week low of $1.23 and a fifty-two week high of $3.95. The firm has a market capitalization of $60.08 million, a P/E ratio of -0.67 and a beta of 0.45. The company's 50 day simple moving average is $1.60 and its 200 day simple moving average is $1.93.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Metagenomi in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.00.

Metagenomi Company Profile

Metagenomi, Inc NASDAQ: MGX is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company's proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi's technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.

Want to see what other hedge funds are holding MGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metagenomi, Inc. (NASDAQ:MGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.